awmsg logo



elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®)


Reference No. 2248

Publication date:
27/07/2016


Appraisal information

elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®) 150mg/150mg/200mg/10mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2216
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download